The short answer
Added low blood pressure or required spacing for dandelion with bumetanide is uncertain. Review the exact preparation and your fluid-management plan before use.
What this answer covers
Oral Herba Taraxaci products with bumetanide. Leaf extract and root-with-herb monograph evidence do not authenticate every aerial-herb preparation.
- Supplement or preparation
- Herba Taraxaci
- Medication ingredient
- bumetanide
Urination changes are not proof of low blood pressure
A one-day pilot in17 volunteers tested a fresh-leaf extract. Urination frequency increased after the first dose and excretion ratio after the second, but the third dose did not change measured outcomes. It did not test bumetanide or demonstrate a clinical hypotension interaction.
The preparation limits the evidence
The pilot used a hydroethanolic leaf extract. A separate monograph covers root with herb and reports no interactions, while advising avoidance in specified conditions including heart or renal failure. Neither source establishes the behavior of every product called Herba Taraxaci.
Review the purpose of additional diuresis
Bumetanide can cause excessive fluid and electrolyte loss if treatment exceeds your needs. More urination is not automatically beneficial, and persistent swelling should prompt review of the treatment plan. Do not increase fluid restriction, the prescription dose or herb use on your own.
Report symptoms and changes
Report persistent dizziness, cramps, weakness, palpitations or a major change in swelling or urine output. Illness, dehydration and other medicines can contribute. Severe weakness, fainting or a new irregular heartbeat need prompt assessment. Do not treat symptoms by adding salts or increasing the diuretic yourself.
Evidence and practical considerations
Side effects & toxicity
The inspected dandelion evidence does not establish excess hypotension or a protective timing interval with bumetanide.
- Exact scope
- Oral Herba Taraxaci products with bumetanide. Leaf extract and root-with-herb monograph evidence do not authenticate every aerial-herb preparation. with Exact bumetanide RxCUI1808 IN, confirmed by current RxNorm. Oral0.5/1/2mg tablets; no automatic IV equivalence or transfer of furosemide-ginseng report.
- Medication form and route
- Oral
What remains uncertain
- One-day leaf pilot, adjacent root-with-herb guidance and no direct combination hypotension outcome; no fixed gap.
Factors that may matter: Exact preparation and dose; Kidney function; Baseline electrolyte status; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral bumetanide tablets.
Potassium loss is dose-related; periodic potassium checks and replacement if necessary. Class magnesium-loss warning and other electrolyte checks in prolonged/high-dose use. Excess diuresis causes fluid/electrolyte depletion.
How this applies: Exact medication label. Exact bumetanide RxCUI1808 IN, confirmed by current RxNorm. Oral0.5/1/2mg tablets; no automatic IV equivalence or transfer of furosemide-ginseng report.
Class magnesium warning is not universal deficiency; healthy low-dose trial and PPI-associated case limitations retained.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 17 volunteers in a single-day pilot.
Urination frequency increased after first dose and excretion ratio after second; third dose did not change measured parameters.
How this applies: Applicability is limited to the stated exact medication, preparation and endpoint; other-drug evidence is indirect.
Abstract-only; no placebo comparison, exact bumetanide or hypotension endpoint. Leaf extract is not every Herba Taraxaci product. Original fullTextXML request404.
Source 3: Regulatory herbal monograph
ema.europa.eu · Source check Sep 10, 2026
Population: Users of defined root-with-herb medicinal preparations.
No interactions reported; avoidance advised in renal failure, diabetes or heart failure because of possible potassium-related risk.
How this applies: Explicit adjacent-preparation and disease boundary.
Root-with-herb preparation differs from Herba Taraxaci; disease precaution is not measured bumetanide hypotension or proof of safety.
Source 4: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
bumetanide is IN.
How this applies: Exact ingredient.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: 2a44f4abecd815ff
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.